2-[4-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-pyrimidine | 942190-00-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[4-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-pyrimidine
• 英文别名: 4-(4-pyrimidin-2-yl-phenyl)-3,6-dihydro-2H-pyridin；2-[4-(1,2,3,6-Tetrahydropyridin-4-yl)phenyl]pyrimidine
• CAS: 942190-00-3
• 化学式: C₁₅H₁₅N₃
• 分子量: 237.304
• InChiKey: WOXKMEXHNKULMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-pyrimidine 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-N-(3-(4-fluorophenyl)-1H-indazol-5-yl)-3-(methylthio)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)ethyl)pyrrolidine-3-carboxamide
  参考文献：
  名称：

  Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology

  摘要：

  Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 mu M h; F% = 0) which precluded further development. In an effort to identify novel ERK inhibitors with improved PK properties with respect to 5, a systematic exploration of sterics and composition at the 3-position of the pyrrolidine led to the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 28 with vastly improved PK (rat AUC PK @10 mpk = 26 mu M h; F% = 70). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.063
• 作为产物：
  描述：

  2-(4-溴苯基)嘧啶 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-[4-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenyl]-pyrimidine
  参考文献：
  名称：

  Discovery of 3( S )-thiomethyl pyrrolidine ERK inhibitors for oncology

  摘要：

  Compound 5 (SCH772984) was identified as a potent inhibitor of ERK1/2 with excellent selectivity against a panel of kinases (0/231 kinases tested @ 100 nM) and good cell proliferation activity, but suffered from poor PK (rat AUC PK @10 mpk = 0 mu M h; F% = 0) which precluded further development. In an effort to identify novel ERK inhibitors with improved PK properties with respect to 5, a systematic exploration of sterics and composition at the 3-position of the pyrrolidine led to the discovery of a novel 3(S)-thiomethyl pyrrolidine analog 28 with vastly improved PK (rat AUC PK @10 mpk = 26 mu M h; F% = 70). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.063

文献信息

• [EN] SPIROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS SPIROCYCLIQUES
  申请人：KALYRA PHARMACEUTICALS INC

  公开号：WO2016161160A1

  公开（公告）日：2016-10-06

  Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

  本文披露了螺环化合物，以及使用本文描述的一种或多种化合物的药物组合物和改善和/或治疗本文描述的癌症的方法。
• Novel compounds that are ERK inhibitors
  申请人：Cooper Alan B.

  公开号：US20090118284A1

  公开（公告）日：2009-05-07

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明公开了式1.0的ERK抑制剂及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环上具有双键。所有其他取代基如本文所定义。本发明还公开了使用式1.0的化合物治疗癌症的方法。
• HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS
  申请人：Sun Robert

  公开号：US20110038876A1

  公开（公告）日：2011-02-17

  Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及公开的ERK抑制剂，其化学式为1.0：[Formula (1.0)]及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个可具有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环中具有双键。所有其他取代基均如所定义。本发明还公开了使用化合物1.0治疗癌症的方法。
• POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS
  申请人：Schering Corporation

  公开号：EP1966151B1

  公开（公告）日：2011-10-05
• SPIROCYCLIC COMPOUNDS
  申请人：Recurium IP Holdings, LLC

  公开号：EP3277690B1

  公开（公告）日：2020-02-26